** Shares of medtech firm Glaukos GKOS.N fall 11.2% to $139.7 premarket
** Co on Thursday posted Q4 net loss of $22.2 mln, vs Wall Street estimate of $20.8 mln loss, as per data compiled by LSEG
** GKOS reported Q4 revenue of $105.5 mln, vs est. of $100.7 mln
** Co forecast 2025 sales in the range of $475 million to $485 million compared with expectation of $479.8 mln
** GKOS's lead product is the iStent inject W, a device used to treat glaucoma, an eye condition that damages the optic nerve
** Stock has risen 75.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.